Analysis of IL-6 marker in synovial fluid of the knee joint in patients with osteoarthritis and rheumatoid arthritis before and after platelet-rich plasma administration

Shaik, Masthan Basha; Vurundhur, Divya; Mallam, Kiran Kumar; Gulabi, Mohammad

doi:10.61186/rabms.10.1.80

Volume 10, Issue 1 (1-2024) Journal of Research in Applied and Basic Medical Sciences 2024, 10(1): 80-87 | Back to browse issues page

‎ 10.61186/rabms.10.1.80

Mendeley

Zotero

RefWorks

Shaik M B, Vurundhur D, Mallam K K, Gulabi M. Analysis of IL-6 marker in synovial fluid of the knee joint in patients with osteoarthritis and rheumatoid arthritis before and after platelet-rich plasma administration. Journal of Research in Applied and Basic Medical Sciences 2024; 10 (1) :80-87
URL: http://ijrabms.umsu.ac.ir/article-1-282-en.html

Analysis of IL-6 marker in synovial fluid of the knee joint in patients with osteoarthritis and rheumatoid arthritis before and after platelet-rich plasma administration

Masthan Basha Shaik ^*

, Divya Vurundhur

, Kiran Kumar Mallam

, Mohammad Gulabi

Associate professor, Department of orthopaedics, ACSR Govt Medical College, Nelore, Andhra Pradesh, India , bonesbasha@gmail.com

Abstract: (1942 Views)

Background & Aims: Platelet-rich plasma (PRP) has emerged as a treatment for osteoarthritis (OA) and rheumatoid arthritis (RA). The aim of the current study is to assess the effect of PRP injection and its influence on interleukin-6 (IL-6) in the synovial fluid of the knee joint in OA and RA patients.
Materials & Methods: Clinico-radiologically diagnosed case of OA and RA of 30 each was included during the study period of 2 years. 10 ml of patient blood collected and PRP was prepared by differential centrifugation method, and this freshly prepared PRP was injected to the affected knee joint slowly. IL-6 levels assessed in synovial fluid at pre-PRP injection and 1^st, 3^rd and 6^th month post-PRP Injection. Pain was measured using Visual Analog Scale.
Results: The mean age of the cases was 58.5 years for OA and 47.2 years for RA. Females were predominantly compared to males. Majority were Kellegren Lawrence radiological grade 3 in 15 (50%) cases, following grade 2 in 8 (26.67%) cases, grade 4 in 6(20%) cases and grade 1 in 1(3.33%) case. Mean IL-6 in OA cases was 89.5±24.5 pg/ml at pre PRP, and 66.48±23.1 pg/ml at post PRP (p<0.001, paired t-test). Mean IL-6 in RA was 97.5±18.9 pg/ml at pre-PRP injection, and 89.6±17.9 at post PRP (p<0.001, paired t-test). In OA cases, paired t-test between the mean pain scores (VAS) at follow-up depicts that the mean difference and standard error of difference between 6-month follow-up and one-month follow-up was -1.23 ± 0.20 statistically significant differences (95%CI: -1.71 to -0.73). In RA cases, paired t-test between the mean pain scores (VAS) at followup depicts that the mean difference and standard error of difference between 6-month follow-up and one-month follow-up was -1.38 ± 0.19 statistically significant differences (95% CI: -1.69 to -0.75). There was a positive correlation between levels of IL-6 and pain score (r=0.309, p=0.004).
Conclusion: Study shows that anti-Inflammatory role of PRP, which was evidenced by the statistically significant difference in the IL-6 levels at follow-up. It may be beneficial to halt the progress in arthritic joints. This study successfully established an anti-inflammatory role of PRP in joint pathology by influencing the IL-6 levels.

Keywords: Interleukin-6, Osteoarthritis, Platelet-Rich Plasma, Rheumatoid Arthritis

Full-Text [PDF 483 kb] (755 Downloads) | | Full-Text (HTML) (647 Views)

Type of Study: orginal article | Subject: Other

References

1. Long H, Liu Q, Yin H, Wang K, Diao N, Zhang Y, et al. Prevalence trends of site-specific osteoarthritis from 1990 to 2019: Findings from the Global Burden of Disease Study 2019. Arthritis Rheumatol 2022;74(7):1172-83. [DOI:10.1002/art.42089] [PMID] []

2. Oliver JE, Silman AJ. What epidemiology has told us about risk factors and aetiopathogenesis in rheumatic diseases. Arthritis Res Ther 2009;11(3):223. [DOI:10.1186/ar2585] [PMID] []

3. Akiyama M, Kaneko Y. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease. Autoimmunity Rev 2022;21(5):103056. [DOI:10.1016/j.autrev.2022.103056] [PMID]

4. Vaishya R, Agarwal AK, Shah A, Vijay V, Vaish A. Current status of top 10 nutraceuticals used for Knee Osteoarthritis in India. J Clin Orthop Trauma 2018;9(4):338-48. [DOI:10.1016/j.jcot.2018.07.015] [PMID] []

5. Jafarzadeh SR, Felson DT. Updated estimates suggest a much higher prevalence of arthritis in United States adults than previous ones. Arthritis Rheumatol 2018;70(2):185-92. [DOI:10.1002/art.40355] [PMID] []

6. Long H, Zeng X, Liu Q, Wang H, Vos T, Hou Y, Lin C, Qiu Y, Wang K, Xing D, Zhang Y. Burden of osteoarthritis in China, 1990-2017: findings from the Global Burden of Disease Study 2017. Lancet Rheumatol 2020;2(3):e164-72. [DOI:10.1016/S2665-9913(19)30145-6] [PMID]

7. Jain S. Arthritis: Freedom from pain. (Last accessed on Dec 2011). Available from: http://www.completewell being.com/article/towards. a. joint. effort/, 2008

8. Wojdasiewicz P, Poniatowski ŁA, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm 2014;2014:561459. [DOI:10.1155/2014/561459] [PMID] []

9. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014;22(3):363-88. [DOI:10.1016/j.joca.2014.01.003] [PMID]

10. Scott LJ. Tocilizumab: A Review in Rheumatoid Arthritis. Drugs 2017;77(17):1865-79. [DOI:10.1007/s40265-017-0829-7] [PMID] []

11. Ip HL, Nath DK, Sawleh SH, Kabir MH, Jahan N. Regenerative medicine for knee osteoarthritis-the efficacy and safety of intra-articular platelet-rich plasma and mesenchymal Stem cells injections: a literature review. Cureus 2020;12(9). [DOI:10.7759/cureus.10575] [PMID] []

12. Kon E, Filardo G, Di Martino A, Marcacci M. Platelet-rich plasma (PRP) to treat sports injuries: evidence to support its use. Knee Surg Sports Traumatol Arthrosc 2011;19(4):516-27. [DOI:10.1007/s00167-010-1306-y] [PMID]

13. Roux‐Lombard P, Eberhardt K, Saxne T, Dayer J-M, Wollheim FA. Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5‐year study. Rheumatology 2001;40(5):544-51. [DOI:10.1093/rheumatology/40.5.544] [PMID]

14. Dhillon MS, Patel S, John R. PRP in OA knee - update, current confusions and future options. SICOT-J 2017;3:27. [DOI:10.1051/sicotj/2017004] [PMID] []

15. Brandt KD, Fife RS, Braunstein EM, Katz B. Radiographic grading of the severity of knee osteoarthritis: relation of the Kellgren and Lawrence grade to a grade based on joint space narrowing, and correlation with arthroscopic evidence of articular cartilage degeneration. Arthritis Rheumatol 1991;34(11):1381-6. [DOI:10.1002/art.1780341106] [PMID]

16. Brenner SS, Klotz U, Alscher DM, Mais A, Lauer G, Schweer H, et al. Osteoarthritis of the knee--clinical assessments and inflammatory markers. Osteoarthritis Cartilage 2004;12(6):469-75. [DOI:10.1016/j.joca.2004.02.011] [PMID]

17. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998;101(2):311-20. [DOI:10.1172/JCI1368] [PMID] []

18. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheumatic Dis 1993;52(3):232-4. [DOI:10.1136/ard.52.3.232] [PMID] []

19. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988;31(6):784-8. [DOI:10.1002/art.1780310614] [PMID]